Work

Annual Congress of the European Association of Nuclear Medicine, October 4–8, 2025 | Barcelona, Spain

Year: 2025

Type: article

Abstract: Rationale 1.Is PSMA-TRT beneficial in the treatment of OSCC …• in monotherapy?• combined with ICI? 2. Do these benefits differ between ...• single high-activity TRT administration (SD-TRT);• fractionated-activity TRT administration (FX-TRT)?† Undefined (> 90 days) * Compared to control (Mantel-Cox log rank test, p < 0.05) ** Compared to control and SD-TRT (Mantel-Cox log rank test, p < 0.05)

Source: EANM Innovation

DOI: 10.1016/s3051-2913(25)00004-7

Authors: Henrotte, Michaël, Creytens, David, De Vos, Filip, Descamps, Benedicte, Devisscher, Lindsey, Holtappels, Gabriële, Huvenne, Wouter, Kersemans, Ken, Meskens, Amber, Neyt, Sara, Rottey, Sylvie, Saerens, Michael, Vanhove, Christian, Vermassen, Tijl, Debacker, Jens

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: Universitair Ziekenhuis Gent, Universiteit Gent, Kom op tegen Kanker, Stand Up To Cancer

OpenAlex ID: W4414119447

FWCI: 2.143

Cites:

Cited by: 4

Related to: 10